Literature DB >> 3612391

Pseudomonas species contamination of cystic fibrosis patients' home inhalation equipment.

K C Pitchford, M Corey, A K Highsmith, R Perlman, R Bannatyne, R Gold, H Levison, E L Ford-Jones.   

Abstract

A prevalence study was undertaken to determine whether aerosol equipment used at home by patients with cystic fibrosis (CF) could provide a reservoir for Pseudomonas aeruginosa or Pseudomonas cepacia. Home maintenance of this equipment was also evaluated for its relationship to contamination. In nine of 36 patients, Pseudomonas species were isolated from one or more pieces of home equipment. Only patients colonized with P. aeruginosa had contaminated equipment. P. aeruginosa was recovered from equipment used by five patients; no P. cepacia was recovered. Aerosolization masks were the most commonly contaminated pieces of equipment (20%), followed by nebulizers (17%), medication syringes (10%), connective tubing (6%), and saline solution (4%). Nebulizers and syringes were significantly more likely to be contaminated if they had been in use for 1 month or longer; nebulizers and masks were more likely to be contaminated if they were cleaned or were rinsed only with tap water after use. We conclude that equipment may serve as a reservoir to reintroduce or perpetuate colonization of some patients with CF, but that contamination of equipment with P. aeruginosa is not common.

Entities:  

Mesh:

Year:  1987        PMID: 3612391     DOI: 10.1016/s0022-3476(87)80069-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  11 in total

1.  2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings.

Authors:  Jane D Siegel; Emily Rhinehart; Marguerite Jackson; Linda Chiarello
Journal:  Am J Infect Control       Date:  2007-12       Impact factor: 2.918

2.  Lung colonization with Aeromonas hydrophila in cystic fibrosis believed to have come from a tropical fish tank.

Authors:  David Cremonesini; Anne Thomson
Journal:  J R Soc Med       Date:  2008-07       Impact factor: 5.344

3.  Nebulised antibiotics for adults with cystic fibrosis.

Authors:  A K Webb; M E Dodd
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

Review 4.  Nebuliser hygiene in cystic fibrosis: evidence-based recommendations.

Authors:  Jane Bell; Lauren Alexander; Jane Carson; Amanda Crossan; John McCaughan; Hazel Mills; Damian O'Neill; John E Moore; B Cherie Millar
Journal:  Breathe (Sheff)       Date:  2020-06

Review 5.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

Review 6.  Infection control in cystic fibrosis.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

Review 7.  [Chronic Pseudomonas aeruginosa airway colonization in cystic fibrosis patients : Prevention concepts].

Authors:  A-M Dittrich
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

8.  Microbial contamination of domiciliary nebulisers and clinical implications in chronic obstructive pulmonary disease.

Authors:  S Jarvis; P W Ind; C Thomas; S Goonesekera; R Haffenden; A Abdolrasouli; F Fiorentino; R J Shiner
Journal:  BMJ Open Respir Res       Date:  2014-02-27

9.  Microbial contamination of home nebulizers in children with cystic fibrosis and clinical implication on the number of pulmonary exacerbations.

Authors:  Seyed Ahmad Tabatabaii; Ghamartaj Khanbabaee; Saeed Sadr; Nazanin Farahbakhsh; Maryam Kazemi Aghdam; Saran Lotfollahzadeh; Amirhossein Hosseini; Naghi Dara; Mohammad Nanbakhsh; Fatemeh Abdollah Gorji
Journal:  BMC Pulm Med       Date:  2020-02-06       Impact factor: 3.317

10.  Effect that an educational program for cystic fibrosis patients and caregivers has on the contamination of home nebulizers.

Authors:  Adriana Della Zuana; Doroti de Oliveira Garcia; Regina Célia Turola Passos Juliani; Luiz Vicente Ribeiro Ferreira da Silva Filho
Journal:  J Bras Pneumol       Date:  2014 Mar-Apr       Impact factor: 2.624

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.